Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30430517 | 1.00 | BCL2A1 (0.45) | BCL2A1CYP2D6SLC6A2SLC6A4NOS2 | |
| SCHEMBL31376029 | 0.83 | BCL2A1 (0.43) | BCL2A1CYP2D6SLC6A2SLC6A4NOS2 | |
| SCHEMBL31535180 | 0.81 | KCNJ1 (0.34) | PGRARTRPV4 | |
| SCHEMBL31388140 | 0.77 | PGR (0.36) | PGRARTRPV4 | |
| SCHEMBL15819822 | 0.77 | CHRM4 (0.43) | AR | |
| SCHEMBL24190442 | 0.77 | FPR2 (0.44) | CYP2D6SLC6A2SLC6A4NOS2PGR | |
| SCHEMBL31376036 | 0.76 | CYP2D6 (0.48) | BCL2A1CYP2D6SLC6A2SLC6A4NOS2 | |
| SCHEMBL21691198 | 0.76 | CYP2D6 (0.48) | BCL2A1CYP2D6SLC6A2SLC6A4NOS2 | |
| SCHEMBL31261067 | 0.75 | CYP2D6 (0.42) | BCL2A1CYP2D6SLC6A2SLC6A4NOS2 | |
| SCHEMBL30718081 | 0.75 | CYP2D6 (0.42) | BCL2A1CYP2D6SLC6A2SLC6A4NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490500-A | PRMT5 inhibitor, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20250000854-A1 | 4-(Aminomethyl)-6-(1-Methyl-1H-Pyrazol-4-YL)Isoquinolin-1(2H)-One Derivatives as MTA-Cooperative Inhibitors of PRMT5 | BEIGENE, LTD. (KY) | 2025-01-02 | — | — | US | disclosed |
| CN-118871432-A | 4- (Aminomethyl) -6- (1-methyl-1H-pyrazol-4-yl) isoquinolin-1 (2H) -one derivatives as MTA synergistic inhibitors of PRMT5 | 百济神州有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023174250-A1 | 4- (AMINOMETHYL) -6- (1-METHYL-1H-PYRAZOL-4-YL) ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE , LTD. (KY) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022192745-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | BCL2A1 1599/4885CYP2D6 3976/4885SLC6A2 4334/4885 |
| US-20250000854-A1 | 4-(Aminomethyl)-6-(1-Methyl-1H-Pyrazol-4-YL)Isoquinolin-1(2H)-One Derivatives as MTA-Cooperative Inhibitors of PRMT5 | PRMT5, PRMT1, PRMT6 | BCL2A1 3325/4885CYP2D6 3593/4885SLC6A2 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.